Revenue - Narrative (Details) - USD ($)						11 Months Ended	12 Months Ended				35 Months Ended
	Dec. 11, 2020	Sep. 19, 2018	Jul. 20, 2015	Sep. 17, 2014	Dec. 17, 2013	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2021	Apr. 17, 2018
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement			$ 250,000	$ 500,000	$ 250,000
Interest in asset			0.50%	1.00%	0.50%
Number of shares issuable term				60 days	60 days
Number of shares issuable (in shares)				62,500	31,250
Grants receivable												$ 7,400,000
Total Revenue								$ 29,625,181	$ 40,519,800
Deferred revenue, period increase (decrease)								1,000,000.0		$ 2,400,000
Deferred revenue as a current liability								354,756	918,272
Research and Development Arrangement December 17, 2013
Disaggregation of Revenue [Line Items]
Recognized as revenue								0	115,900
Research and Development Arrangement September 17, 2014
Disaggregation of Revenue [Line Items]
Recognized as revenue								0	313,700
Research and Development Arrangement July 20, 2015
Disaggregation of Revenue [Line Items]
Recognized as revenue								0	$ 214,300
Research And Development Arrangement September 19, 2018
Disaggregation of Revenue [Line Items]
Total Revenue								700,000
Grant
Disaggregation of Revenue [Line Items]
Total Revenue								1,600,000		$ 2,000,000.0
Grant | Scenario, Forecast
Disaggregation of Revenue [Line Items]
Total Revenue						$ 1,800,000					$ 5,600,000
Biomedical Advanced Research and Development Authority (BARDA)
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement	$ 3,500,000
Biomedical Advanced Research and Development Authority (BARDA) | Scenario, Forecast
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement							$ 6,500,000
Biomedical Advanced Research and Development Authority (BARDA) | Plan
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement		$ 4,600,000						$ 8,100,000